Bosutinib; Dasatinib; Erlotinib; Nilotinib/Antacids
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
The pH of your GI tract needs to be acidic for your cancer medicine to dissolve and be absorbed. Antacids change the pH (acidity) of your GI tract.
What might happen:
Taking your cancer medicine at the same time as an antacid may decrease the amount of dasatinib in your blood and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may instruct you to take antacids instead of other medicines for heartburn/ulcers such as H-2 blockers (e.g. cimetidine, famotidine, nizatidine, ranitidine) or proton-pump inhibitors (e.g. esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole).If you need to use an antacid while on bosutinib, dasatinib, or nilotinib, take the antacid at least 2 hours before or 2 hours after your bosutinib or dasatinib.If you need to use an antacid while on erlotinib, separate the times you take the antacid and your cancer medicine by several hours.If you have questions about how to schedule your medicines, ask your pharmacist.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Bosulif (bosutinib) US prescribing information. Pfizer Inc. August, 2012.
2.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company June, 2013.
3.Tarceva (erlotinib) US prescribing information. Genentech, Inc. April, 2012.
4.Tasigna (nilotinib) US prescribing information. Novartis Pharmaceuticals Corporation June, 2013.